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ABSTRACT
Objective: The RCAa block (Regulators of Complement
Activation, 1q32) contains critical complement regulatory
genes such as CR1 and MCP. This study examined RCAa
block haplotype associations with both disease suscept-
ibility and diversification of the anti-Ro/La autoantibody
response in primary Sjo ¨gren syndrome (pSS).
Methods: 115 patients with pSS and 98 controls were
included in the study. 93 of 109 (85%) of the patients
with pSS were seropositive for Ro/La autoantibodies. The
Genomic Matching Technique (GMT) was used to define
RCAa block ancestral haplotypes (AH).
Results: RCAa block haplotypes, AH1 and AH3, were
both associated with autoantibody-positive pSS
(p=0.0003). Autoantibody associations with both HLA
DR3 and DR15 have been previously defined. There was
an epistatic interaction (p=0.023) between RCAa AH1
and HLA DR3, and this genotypic combination was
present in 48% of autoantibody-positive patients with pSS
compared with 8% of controls. This epistasis is most
simply attributable to an interaction between C4 and its
receptor, CR1, encoded within the RCAa block. Both DR3
and a relative C4 deficiency are carried on the major
histocompatibility complex 8.1 ancestral haplotype. Only
four of 92 (4%) autoantibody-positive patients with pSS
did not carry any risk RCAa or HLA haplotype, compared
with 36 of 96 (38%) controls, and there were differences
in haplotype frequencies within autoantibody subsets of
pSS.
Conclusions: Normal population variation in the RCAa
block, in addition to the major histocompatibility complex,
contributes genetic susceptibility to systemic autoimmune
disease and the autoantibody response. This finding
provides evidence for the role of regulation of complement
activation in disease pathogenesis.
Primary Sjo ¨gren syndrome (pSS) is a systemic
autoimmune disease, which shares a number of
clinical, serological and genetic features with
systemic lupus erythematosus (SLE).
1 One of the
features of this disease is the high prevalence of
autoantibodies to the Ro and La components of a
ribonuclear protein (RNP) complex. Ro/La auto-
antibodies occur in individual patients as targeting
either Ro alone, or with specificity to both Ro and
La, and autoantibody subgroups are stable over
time. Major histocompatibility complex (MHC)
disease associations have been known for many
years,
23and more recently it has been recognised
that these MHC haplotypes regulate the diversi-
fication of the autoantibody response.
45 Ro/La
autoantibodies occur in other rheumatological
diseases such as SLE; however, they are highly
specific for pSS and constitute one of the
classification criteria for this disease.
6 Serum Ro/
La autoantibodies have been shown to pre-date
disease onset, often for many years, and seropo-
sitivity predicts disease severity and extraglandu-
lar features in patients with pSS.
7 More recently, a
pathogenic role has been proposed as Ro/La
autoantibodies form nucleic-acid-containing
immune complexes that can trigger prolonged
type I interferon production, leading to a self-
perpetuating autoimmune reaction.
8
Deficiencies in the classical pathway of the
complement system have been implicated in the
aetiology and pathogenesis of autoimmune dis-
eases such as SLE.
9 Human complement receptor 1
(CR1, CD35) is an integral membrane complement
control protein (CCP) whose primary role on
erythrocytes is the non-inflammatory clearance of
immune complexes opsonised with C3a and C4b.
There is longstanding evidence, over 25 years in
our own papers,
10 for an acquired CR1 deficiency in
SLE. A recent meta-analysis has demonstrated an
association between a molecular weight variant of
CR1 and SLE.
11 Further, in the mouse, CR1/CR2
(encoded by alternatively spliced forms of the same
gene) is a lupus susceptibility gene
12 13 important in
the modulation of the antinuclear autoantibody
response.
14 15
Human CR1 is located at 1q32 in the regulators
of complement activation (RCA) complex, which
also includes other complement regulatory encod-
ing genes, namely factor H (CFH), complement 4 a
and b binding protein’s (C4ABP and C4BBP), decay
accelerating factor (DAF, CD56), complement
receptor 2 (CR2, CD21) and membrane cofactor
protein (MCP, CD46).
Encompassing some 13 Mb of the long arm of
chromosome 1, the RCA does not contain an even
distribution of CCPs. In fact all CCPs can be
found within one of two distinct blocks, located
at the telomeric and centromeric ends of the
cluster, we refer to these as the a and b blocks
respectively. Both blocks are about 500 kb in
length and are characterised by extensive imper-
fect genomic duplication and degeneracy gener-
ated by insertions and deletions (indels) such as
those created through domain duplication/dele-
tion and retroviral insertion. CR1 is encoded
within the RCAa block, where it has been
duplicated as part of a segment along with
MCP-Like, to form CR1-L and MCP (or vice
versa). Segment A (CR1 and MCP-L) and B (CR1-
L and MCP) are located next to each other and
encompass ,350 kb of the a block.
16
As demonstrated some time ago within the
MHC,
17–19 and more recently throughout the entire
genome,
20–22 genomic blocks are normally defined
by gene and segmental duplications while also
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nation and an increased frequency of copy number, indel and
single nucleotide polymorphisms.
23 A consequence of recombi-
nation suppression is that haplotypes of these regions are likely
to have been inherited faithfully over many generations (ie,
ancestral haplotypes (AH)) and will therefore be important in
defining complex genetic interactions.
24
We recently reported a novel haplotyping approach, capable
of interrogating the genetically complex RCAa block, by
utilising the genomic duplication of CR1 and MCP (segment
A and segment B).
25 The assay uses the principles of the
Genomic Matching Technique,
23 used by us, and other groups,
to interrogate the highly complex MHC region for the
identification of donor/recipient matches prior to bone marrow
transplantation.
26–29 More recently the technique has been
extended to forensic applications
30 and used within the RCA
complex on chromosome 1
25 and the class II region of the canine
MHC.
31 The technique involves the specific amplification, with
a single primer pair, of multiple complex geometric elements, all
linked and located within duplicated segments. The conceptual
basis behind the technique is that duplicated elements make
excellent haplospecific markers as they have evolved in line with
the many other changes that have also occurred on each
haplotype.
The aim of this study was to evaluate RCAa block
haplotypes, as defined by the Genomic Matching Technique
(GMT), in relation to both disease susceptibility and Ro/La
autoantibody responses in patients with pSS. Specifically we
hypothesised that genetic variation in the RCAa, in combina-
tion with HLA, would influence the diversification of the Ro/La
autoantibody response.
MATERIALS AND METHODS
Study participants
Ninety-eight Caucasian controls and 115 Caucasian patients
with pSS from the South Australian Sjo ¨gren syndrome
research registry were included in the study. All patients
met the revised 2002 American-European consensus research
classification criteria for pSS,
6 and controls were recruited
from the same population base as the patients. Anti-Ro/La
autoantibody specificity was determined by enzyme-linked
immunosorbent assay (RELISA ANA Screening System,
Immuno Concepts NA, Sacramento, California, USA) using
recombinant Ro60 and La proteins, as part of standard
diagnostic procedure. Sera from patients with anti-La were
further tested by counterimmunoelectrophoresis (CIEP)
32 to
confirm whether or not anti-La antibodies detected by
enzyme-linked immunosorbent assay were able to be detected
by this method. HLA typing of patients with pSS (serological
HLA-B and molecular DRB1) was performed by the
Transplantation Laboratory, Australian Red Cross Blood
Service, SA Division. Molecular DRB1 typing of the controls
was performed by Conexio Genomics (Applecross, WA,
Australia). The study was approved by the Human Ethics
Committee of The Queen Elizabeth and Royal Adelaide
Hospitals and all patients gave informed, written consent.
RCAa block haplotyping
Haplotypes of the RCAa block were obtained using the GMT
assays as previously described.
25 Briefly, two separate polymer-
ase chain reaction reactions using primer sets CR1MCP5&6 and
CR1MCP11&12 were performed on each genomic DNA sample.
Each primer set was designed to amplify a duplicated element,
located within the CR1 region of both segments (segment A
containing CR1 and MCP-Like and segment B containing CR1-
Like and MCP). The resulting mix of polymerase chain reaction
products were used to define the haplotypic variation within
the RCAa block. The polymerase chain reaction products were
separated on the basis of size on a Corbett Research GS-3000
automated gel analysis system (Corbett Research (Australia),
Mortlake, NSW, Australia). Haplotype assignment and nomen-
clature are as previously described.
25
Statistical analysis
Contingency table analysis of haplotype and genotype frequen-
cies in patients with pSS versus controls was performed by
multivariate logistic regression using both additive and domi-
nant allele coding. Associations were further reported as odds
ratios (OR) with 95% confidence intervals (CI) obtained by back
transformation of the regression coefficients.
RESULTS
RCAa block haplotype diversity
We have previously demonstrated substantial polymorphism in
GMT RCAa block haplotypes.
25 More than 20 haplotypes have
been defined, although the majority are rare. In the current
study of 213 Caucasians (pSS and controls combined), there
were three relatively common haplotypes (AH1, AH2 and AH3
as designated by McLure et al
25 each with a frequency of .10%.
These three haplotypes combined accounted for 56% of the
total haplotypes in the sample. There were a further 14
haplotypes with a frequency between 1 and 3%. These
frequencies were considered too low to be informative given
the study sample sizes and were therefore combined for analysis
purposes. RCAa block genotypes were in Hardy–Weinberg
equilibrium in both patients with pSS and controls (p=0.93,
p=0.21 respectively, exact test).
RCAa block haplotypes are associated with Ro/La autoantibody-
positive primary Sjo ¨gren syndrome
CR1 haplotype frequencies were significantly different between
patients with pSS and controls (global x
2=14.6, df=3,
p=0.002, table 1). Both AH1 (OR 2.1, 95% CI 1.3, 3.3) and
AH3 (OR 2.4, 95% CI 1.3, 4.4) were significantly increased in
pSS relative to controls implying an association between both of
these haplotypes and susceptibility to pSS. However, this
association was primarily attributable to the Ro/La autoanti-
body-positive subgroup of patients with pSS (n=96,
p=0.0003) and was not evident in the relative minority of
patients with pSS who were autoantibody negative (n=19,
p=0.68).
Table 1 RCAa haplotype frequencies in patients with pSS compared
with controls
Haplotype
pSS
(2N=230)
Controls
(2N=196) OR (95% CI) p Value
AH1 80 (34.8%) 46 (23.5%) 2.1 (1.3,3.3)* 0.002
AH2 25 (10.9%) 27 (13.8%) 1.3 (0.6,2.1) 0.75
AH3 38 (16.5%) 19 (9.7%) 2.4 (1.3,4.4) 0.006
Other 87 (37.8%) 104 (53.1%) 1
Global test: x
2=14.6, df=3, p=0.002
There were three common RCAa block ancestral haplotypes, AH1, AH2 and AH3.
‘‘Other’’ haplotypes, with a frequency between 1 and 3%, were combined for analysis
purposes. Both AH1 and AH3 frequencies were increased in patients with pSS relative
to controls. This association was attributable to the Ro/La autoantibody-positive
subgroup of patients with pSS and was not evident in the minority of patients with
pSS who were autoantibody negative (2N=38).
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the frequencies of all genotypes carrying either AH1 or AH3
were increased in Ro/La autoantibody-positive patients with
pSS compared with controls (fig 1). This was accompanied by a
striking concomitant decrease in the frequency of all other (X,X)
genotypes. There was significant departure from an additive or
allele dose model (p=0.043) by logistic regression analysis, and
the data were most consistent with both AH1 and AH3 exerting
dominant genotypic effects. Under the dominant model, AH1
and AH3 appeared to be independently associated with
autoantibody-positive pSS as there was no evidence of any
interaction (p=0.258). The odds ratios for the dominant
genotypic association with autoantibody-positive pSS were 3.8
(95% CI 2.0, 7.3, p=0.0001) for AH1 and 4.1 (95% CI 1.9, 8.7,
p=0.0003) for AH3. The association for the compound
heterozygous AH1,AH3 genotype was predicted by multi-
plication of these odds ratios.
Epistatic interaction between the RCAa block and the major
histocompatibility complex in susceptibility to Ro/La
autoantibody-positive pSS
An association between both HLA-DRB1*0301 (DR3) and HLA-
DRB1*1501 (DR15) and autoantibody-positive pSS is well
established in Caucasians.
45 Therefore it was of interest to
examine relationships between MHC and RCAa block associa-
tions with autoantibody-positive pSS.
Analysis of the cross-classification of HLA-DR3, DR15 and
RCAa AH1 and AH3 genotypic combinations in autoantibody-
positive patients with pSS (n=92) versus controls (n=96) was
performed by multivariate logistic regression using dominant
coding and all two-factor interaction terms were evaluated. The
odds ratios from this analysis are illustrated in fig 2A. HLA DR3,
DR15 alleles and the RCAa AH3 haplotype were independent
risk factors for autoantibody-positive pSS, with similar effect
sizes. Therefore, the association for compound heterozygous
genotypes was predicted by multiplication of these odds ratios.
However, there was a disproportionately increased frequency of
patients with pSS who carried both HLA DR3 and RCAa AH1
(interaction term, p=0.021) demonstrating an epistatic rela-
tionship.
33 In the absence of RCAa AH1, HLA DR3 was still
associated with Ro/La-positive pSS (OR 2.7, p=0.025),
although the association was greatly enhanced by the presence
of AH1 in the same individual (OR 15.7, p=10
28). Conversely,
the RCAa AH1 association was not associated with genetic
susceptibility to pSS in the absence of DR3 (OR=1.3, p=0.6).
Moreover, this epistatic genotypic combination of HLA DR3
and RCAa AH1 was the largest genetic risk factor for
autoantibody-positive pSS. It was highly specific for autoanti-
body-positive pSS as it was present in 44 of 92 (48%) patients
with pSS who were Ro/La autoantibody positive compared
with only eight of 96 (8%) controls (fig 2B). The majority of
patients with pSS who did not carry this epistatic genetic risk
factor carried any combination of DR3/DR15/AH3, the other
risk genotypes identified in the analysis. Therefore, only four of
92 (4%) autoantibody-positive patients with pSS did not carry
any risk genotypes compared with 36 of 96 (38%) of controls.
Genetic associations with Ro/La autoantibody subsets in primary
Sjo ¨gren syndrome
Of 115 patients with pSS, 19 (16%) were negative and 97 (84%)
positive for anti-Ro/La autoantibodies. Seropositive Ro+La
patients by enzyme-linked immunosorbent assay were further
subdivided into non-precipitating La, ie, Ro+La (ppt–), or
precipitating, ie, Ro+La (ppt+), on the basis of a precipitin line
formed by anti-La antibodies on CIEP. Therefore, in addition to a
seronegative subset, seropositive patients with pSS were classified
into one of three serological subsets: anti-Ro alone (19 of
115=16%), anti-Ro+La(ppt2) (22 of 115=19%) and anti-
Ro+La(ppt+) (55 of 115=46%). These subgroups are charac-
terised by increasing titre and a more polyclonal autoantibody
responseinaddition tohigherrheumatoidfactorandIgGlevels.
43 2
We, and others
45have previously demonstrated that HLA-
DR3 and DR15 frequencies differ between autoantibody
subsets, and this question is also of interest in relation to the
RCAa haplotypes. The phenotypic prevalences of DR3, DR15
and RCAa AH1 and AH3 in controls, seronegative pSS and the
three pSS autoantibody subsets are displayed in fig 3. While the
data are difficult to interpret definitively because of the
relatively small sample sizes in three of the serological subsets,
some inferences may be drawn.
The increased prevalence of HLA DR3 in autoantibody-
positive pSS is largely B8-DR3, which is carried on the 8.1
ancestral haplotype. B8-DR3 is most strongly associated with
the polyclonal Ro+La (ppt+) autoantibody response, whereas, as
previously reported,
4 DR15 is almost exclusively associated with
the restricted Ro+La (ppt2) response. The RCAa AH1
prevalence, although elevated, is relatively constant in autoanti-
body-positive patients. The basis for the epistatic interaction
between RCAa AH1 and DR3 is most likely restricted to the 8.1
ancestral haplotype, rather than other DR3 containing haplo-
types, and may exert a primary influence on the autoantibody
response in pSS. Interestingly, 8.1 ancestral haplotype only one,
rather than two or more C4 genes and is therefore associated
with a relative C4 deficiency.
34 However, there are clearly other
genes on the MHC 8.1 haplotype that contribute additionally to
regulation of the autoantibody response. The RCAa AH3
haplotype has the highest prevalence in patients with anti-La
Figure 1 RCAa ancestral haplotype (AH) 1 and AH3 genotype
frequencies in patients with primary Sjo ¨gren syndrome who were Ro/La
autoantibody positive compared with controls. There was a significant
departure from an additive or allele dose model (p=0.043) by logistic
regression analysis, and the data are most consistent with AH1 and AH3
exerting dominant effects of similar size. Under the dominant model, AH1
and AH3 appear to be independently associated with autoantibody-
positive primary Sjo ¨gren syndrome, ie, with multiplicative risks.
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body response.
The genes for C2 are also in the extended MHC region and
type 1 C2 deficiency is encoded within the 18.1 haplotype,
which carries B18-DR15. There was no evidence of any epistatic
interaction between RCAa block haplotypes and DR15. Further,
only four B18-DR15 (from a total of 52 DR15) haplotypes were
observed in patients with pSS and, as expected, there were no
associations.
DISCUSSION
The GMT haplotyping approach has been used in this study to
identify AH of the RCAa block and their associations with pSS,
a systemic autoimmune disease. Duplication and copy number
variation reveal more genetic diversity than single nucleotide
polymorphisms,
19 35 yet for most haplotyping assays, interpret-
ing the results and defining haplotypes in these regions is
difficult. The GMT assay is useful in interrogating complex
genomic regions, such as the MHC and RCA blocks, as it
requires and utilises these features to efficiently define the
genomic polymorphism and AH within the region. The GMT
RCAa block haplotyping has revealed extensive haplotypic
polymorphism in this region (which also includes CR1-L, MCP
and MCP-L genes), with more than 20 AH defined,
25 although
the majority are rare.
In this study we report that relatively frequent RCAa block
haplotypes, AH1 and AH3, are associated with pSS, an
autoimmune disease with a high prevalence of antinuclear Ro/
La autoantibodies, and which shares both clinical and genetic
susceptibility overlap with SLE.
The RCAa block contains CR1, CR1-L, MCP and MCP-L
genes, and possibly also CR2, although the boundaries of the
block have not been precisely defined. Erythrocyte CR1 in
humans provides an important mechanism for the non-
inflammatory clearance of immune complexes opsonised with
C3a and C4b, and genetic variation in CR1 expression and/or
function may influence both the predisposition to autoanti-
body-mediated disease (the clearance hypotheses)
36 and self-
perpetuating autoimmune reactivity resulting from prolonged,
immune complex-mediated, type I interferon production.
8
Although an acquired loss of erythrocyte CR1 expression has
been observed in diseases such as SLE and pSS, the phenotypic
high/low CR1 expression polymorphism is not associated with
SLE,
11 although the genetic basis for this is not well defined.
CR1 expression is downregulated by immune complexes and
upregulated by interferon c in SLE,
37 and in the mouse, CR1/
CR2 expression (encoded by the same gene) is upregulated by
BAFF.
38 Therefore, genetic differences in the compound regula-
tion of CR1 expression are likely to be strongly influenced by
the complex inflammatory disease milieu.
In addition to clearance of immune complexes, CR1 and CR2
play a direct, instructive role in setting the threshold for B cell
responses to antigen
39 and potentially, the loss of B cell
tolerance,
40 a fundamental step in the pathogenesis of auto-
immune disease. Further, cross-linking of MCP (CD46) with the
TCR on naı ¨ve CD4+ T cells induces regulatory T cells,
41 which
are critical in the balance between autoimmunity and toler-
ance.
42
Finally, complement control proteins may function as
receptors for ligands other than complement components. The
CR2 receptor is of particular interest in this regard, and a recent
study has demonstrated an association between a common CR2
single nucleotide polymorphism based haplotype and SLE.
43.
CR2 is not only a functional receptor for interferon a,
44 but is
also the Epstein–Barr virus (EBV) receptor. There has long been
a strongly suspected link between EBV infection and systemic
autoimmunity. Intriguingly, molecular mimicry between the
EBNA-1 epitope of the EBV virus and the Ro autoantigen has
been demonstrated in initiation of the anti-Ro response in
patients who ultimately developed SLE.
45
Similar to HLA haplotypes, RCAa block haplotypes exert an
influence on Ro/La autoantibody responses in patients with
pSS. Importantly, there was an epistatic interaction between
RCAa AH1 and HLA B8-DR3 in patients with pSS with Ro/La
autoantibodies, which is indicative of a biological relationship
between gene products of these haplotypes and disease path-
ways. The most likely basis for this epistasis is an interaction
Figure 2 Epistatic interaction between the MHC and RCAa block in Ro/
La autoantibody-positive patients with primary Sjo ¨gren syndrome (pSS).
(A) Odds ratios (y-axis, logarithmic scale) derived by logistic regression
for the cross-classification of HLA DR3, DR15 and RCAa AH1, AH3
genotypic combinations (dominant coding) in Ro/La autoantibody-
positive patients with pSS (n=92) relative to controls (n=98). The
vertical bars represent 95% confidence intervals, and the horizontal line
represents an odds ratio of 1 (no effect). HLA DR3, DR15 alleles and the
RCAa AH3 haplotype were independent risk factors for autoantibody-
positive pSS (ie, multiplicative risks), but there was an epistatic
interaction between HLA DR3 and RCAa AH1 (interaction term
p=0.021). The genotypic combination of HLA DR3 and RCAa AH1 was
the greatest genetic risk factor for autoantibody-positive pSS (OR 15.7,
p=1028), but in the absence of DR3, there was no effect of RCAa
AH1. (B) Pie chart depicting the relative proportions of risk genotypes.
The HLA DR3–RCAa AH1 epistatic combination was present in 48% of
autoantibody-positive patients with pSS compared with 8% of controls.
The majority of other patients with pSS carried any combination of HLA
DR3, DR15 and RCAa AH3.
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for C4 are in the extended MHC region. HLA B8-DR3 and a
relative C4 insufficiency (C4A*Q0,C4B*1)
34 are both part of the
8.1 ancestral haplotype. The genetic structure of the C4 region
is itself complex and highly polymorphic with both allelic and
copy number variation of C4A and C4B genes.
46 Genetic
variation in C4 is known to contribute to disease susceptibility
associated with MHC haplotypes
47–49, but other MHC genes are
also likely to be involved.
34 48 In addition to systemic diseases
such as pSS and SLE, the MHC 8.1 haplotype is associated with
a number of organ-specific autoimmune diseases such as type 1
diabetes mellitus, Hashimoto’s thyroiditis, Graves’ disease,
myasthenia gravis and multiple sclerosis. Evaluation of RCAa/
MHC interactions in these diseases, and their association with
susceptibility, autoantibody production and clinical phenotype
would clearly be of great interest.
In addition to demonstrating the utility of the GMT
approach for interrogating polymorphism in complex genomic
regions, this study has also demonstrated that normal popula-
tion variation in the RCAa block contributes substantially to
susceptibility to systemic autoimmune disease. This is therefore
direct evidence of the importance of regulation of complement
activation in disease pathogenesis. The differing functional
effects of the RCAa block haplotypes have not yet been defined
and will be the focus of future research. These are likely to be
pleiotropic and may well involve further epistatic genetic
interactions. Although the task of unravelling these effects will
be highly complex, we predict they will provide important
insights into underlying autoimmune disease mechanisms.
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